OWP Pharmaceuticals is showcasing Subvenite at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Subvenite addresses a real clinical gap — patients who can't swallow lamotrigine tablets (pediatric, elderly, dysphagia, institutionalized). At APA, they'll target psychiatrists managing bipolar patients in these specific populations. EVERSANA commercial partnership for distribution.
Ask about: Target prescriber population and uptake since Sept 2025 launch; pricing vs. generic lamotrigine tablets; institutional/long-term care facility adoption; pipeline of other liquid psychiatric formulations (trazodone, atomoxetine, quetiapine, duloxetine — all in development).
ePRO+ captures real-world adherence improvements in patients switching from tablets to liquid — critical formulary justification evidence. Video-based assessments especially relevant for populations that benefit most (pediatric, elderly, residential).
Position as the adherence evidence generation platform.
Set up a follow-up with OWP Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →